whitepaper MEA to probe ALS phenotypes in neuronal disease models 6 February 2024 | By bit.bio Explore an MEA workflow used to validate the ALS-relevant phenotype of precision reprogrammed iPSC-derived neuronal disease models of ALS from bit.bio
whitepaper Consistent, functional lower motor neurons from iPSCs 26 January 2024 | By bit.bio How pure consistent and functional lower motor neurons can be precision reprogrammed from iPSCs for motor neuron disease research and drug discovery.
whitepaper Application note: Developing next-gen in vitro Huntington’s disease assays 23 February 2023 | By bit.bio The use of high-density MEAs to probe single cell and network activity electrophysiology of a hiPSC-derived Huntington’s disease model
whitepaper Infographic: Differentiating iPSCs – Which approach works best? 20 September 2022 | By bit.bio Download this infographic to find out why the method of generating human iPSC-derived cells matters.
whitepaper Product hub: A reproducible and scalable Huntington’s disease human cell model 22 June 2022 | By bit.bio Senior scientist Dr Tony Oosterveen discusses bit.bio’s new ioDisease Model portfolio, including new models for Huntington’s disease to help advance in vitro research and drug discovery.
news bit.bio raises $103 million in first close of Series B financing 9 November 2021 | By bit.bio The funding will accelerate clinical development of cell therapies using breakthrough gene engineering technology opti-oxTM.
